Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


To Be “Fit For 2018,” Merck Serono Hints At Earlier Stage Deals, But India May Have To Wait

This article was originally published in PharmAsia News

Executive Summary

The world’s oldest drug maker is gearing up to be a leaner machine by 2018, relying on studying data closely before signing deals.

You may also be interested in...

Merck KGaA's Softly-Softly Approach To German Cutbacks Shows Learning From Swiss Experience

Merck KGaA is in learning mode as it calls for early retirements and voluntary redundancies in Germany, instead of more abrupt action. Around 10% of jobs at Merck KGaA in Germany are at risk, but the company will refrain from forced job losses until the end of 2017.

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Lee Takes India Compulsory License Fight To Saxagliptin

In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts